Overview

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to determine the effect of timing of Zometa® administration on bone mineral density of the lumbar spine and femoral neck in men undergoing androgen deprivation therapy for prostate adenocarcinoma. In addition, the researchers will also determine the effects of treatment with Zometa® on peripheral blood markers of bone turnover, on peripheral blood gd T-cell frequencies and function, and to determine if the above treatments elicit prostate antigen-specific IgG immune responses. The effects of the above treatments on serial serum PSA measurements will also be examined.
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborator:
Novartis Pharmaceuticals
Treatments:
Androgens
Diphosphonates
Leuprolide
Zoledronic Acid